This article has Open Peer Review reports available.
“Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report
© Breuer et al. 2015
Received: 5 May 2015
Accepted: 8 October 2015
Published: 31 October 2015
Misuse of various new psychotropic substances such as ibogaine is increasing rapidly. Knowledge of their negative side effects is sparse.
We present a case of intoxication with the herbal substance ibogaine in a 22-year-old white man. After taking a cumulative dose of 38 g (taken in two doses), he developed visual memories, nausea and vomiting. He developed a generalized tonic–clonic seizure with additional grand mal seizures. He was treated with midazolam and levetiracetam. Extended drug screenings and computed tomography and magnetic resonance imaging findings were all negative.
Knowledge of the side effects of ibogaine has mainly come from reports of cardiovascular complications; seizures are rarely mentioned and experimental findings are inconsistent. It seems that ibogaine acts like a proconvulsive drug at high doses.
The use of synthetic legal or semi-legal substances is increasing rapidly, especially in patients under the age of 30 years [1–4]. One such substance is ibogaine, a natural alkaloid extracted from the roots of the rain forest shrub Tabernanthe iboga. Ibogaine is known in alternative and rural medicine. In Gabon it is used for initiation ceremonies to induce a near-death experience for psychological purposes and to produce a rural-spiritual contact with the ancestors. It acts as a traditional “high” that includes hallucinations and feelings of depersonalization.
In Western countries, the substance is used off-label and experimentally for the specific indication of detoxification from opiates, stimulants, alcohol and nicotine; in particular, it is used to treat withdrawal symptoms [5, 6]. Anticonvulsive and stimulant in vitro and in vivo effects were described for ibogaine . The most commonly used form is the hydrochloride salt of ibogaine (HCl), but alkaloid extracts or dried root bark are also used. Experimental findings suggested that ibogaine elevates plasma prolactin and corticosterone levels and that it is involved in decreasing dopamine (DA) neurotransmission. Ibogaine also decreases neurotransmission of serotonin receptors (5-hydroxytryptamine; 5-HT) in the striatum [7–11]. The anticonvulsive mode of action occurs via an N-methyl-d-aspartate (NMDA) receptor antagonism, a finding that has been well documented in experimental and therapeutic examinations [8, 12, 13].
The psychoactive state associated with ibogaine has been likened to a waking dream/dreamy state that sometimes includes interrogatory verbal exchanges. Another described experience is panoramic memory or the recall of rapid dense successions of autobiographical visual memories. These experiences have been associated with functional muscarinic cholinergic effects, which are prominent in the mechanisms of dreaming and memory [14, 15]. Ibogaine is used most frequently as a single oral dose in the range of 10 to 25 mg/kg of body weight. In the USA and most European countries, ibogaine is classified as an illegal drug [15, 16].
We report the case of a 22-year-old white man in good physical health (body height of 184 cm; body weight of 76.6 kg) who used ibogaine for the first time; he had no history of acute or chronic illness and no history of any drug dependence. He had no concomitant use of prescribed medications. Prior to admittance he had not taken any somatic medication for approximately 6 months.
Apparatus and laboratory findings during the observation period after ibogaine intoxication
Type of analysis
No pathological findings
Magnetic resonance imaging
No pathological findings
Sinus tachycardia (>120 beats per minute)/Sinus rhythm
Sinus rhythm 55 beats per minute; QTc: 100 %
Irregular alpha rhythm, significant portion of diffuse theta waves, no focal slowing, no epileptiform discharges
Regular alpha rhythm, no focal slowing, no epileptiform discharges
White blood cell count (×103/μl)
Platelet count (×103/μl)
Lymphocyte count (%)
Neutrophil count (%)
C-reactive protein (mg/l)
Carbohydrate-deficient transferrin (%)
Ibogaine concentration in hair sample (pg/mg)
Noribogaine concentration in hair sample (pg/mg)
Noribogaine concentration in urine sample (ng/mg)
Knowledge about the potential side effects of ibogaine is sparse. Sudden deaths have been related to the use of ibogaine, mainly because of concomitant medication use and comorbidities (especially cardiovascular) and/or its use among drug users as a self-treatment for detoxification. Most reports have noted fatal cardiac symptoms with QT prolongation and cardiac arrhythmias [17, 18]. By contrast, our patient survived without any detected severe electrocardiogram (ECG) abnormalities. Alper et al. reported the case of a patient who presented observed and well-documented seizures directly related to ibogaine, which the patient did not take for detoxification purposes . In addition to the known psychotropic effects, our patient showed additional reactive generalized epileptic seizures caused by ibogaine. He had no additional history of drug abuse, so a substance-induced trigger could be excluded. Also an interaction of ibogaine with prescribed substances as a potentiator of the seizure events could be excluded in this case.
This description of a seizure induction via ibogaine misuse is rare and is in contrast to the supposed anticonvulsive mode of action via NMDA receptor antagonism of ibogaine which seems to mediate the anticonvulsive effects of the substance [20, 21]. In clinical settings a paradoxical seizure exacerbation by anti-epileptic medication is a known clinical phenomenon but the cellular mechanisms still remain unclear [22, 23]. One possible explanation might be an enhanced disinhibition process by a dose-dependent suppression of inhibitory interneurons. Ibogaine like MK-801 (dizocilpine) also stimulates a release of glucocorticoids that in turn increase susceptibility to seizures. The seizures observed in our patient could be related to the same glucocorticoid effect .
Binienda et al. described that MK-801 (dizocilpine) which also acts as an NMDA antagonist, paradoxically enhances electrographic seizures that preceded suppression of status epilepticus .
Although we cannot provide the exact ibogaine concentration of the dried root bark that our patient used, a dose of 38 g is high compared with the doses of 2 to 30 g of dried ibogaine root bark reported in literature . Assuming an ibogaine concentration of 7 %, as previously reported , this would have corresponded to a single ingestion dosage of 2260 mg, or 35 mg/kg. It can be assumed that in our patient’s case, ibogaine acted like a high-dose-dependent proconvulsive drug while in lower doses being generally supposed to have an anticonvulsive mode of action.
This finding could stimulate further experimental studies to examine this hypothesis of a dose-dependent convulsive mode of action of ibogaine.
It seems that in addition to its psychotropic and cardiac risk profile, ibogaine also has a substantial proconvulsive mode of action that is atypical given its NMDA antagonism, and this is potentially dose dependent. Of course, the significance of this finding is limited because only one documented case exists. Nevertheless, more case examinations and experimental findings could probably prove this hypothesis of a dose-dependent proconvulsive mode of action of ibogaine in higher consumed doses. These upcoming examinations should integrate and control for experimental findings that postulate that ibogaine has anticonvulsive effects . Overall, taking into account the rising consumption of extraordinary herbal substances and the increasing number of reported side effects, physicians should be aware of this clinical manifestation of ibogaine use.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding program Open Access Publishing.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32:1–28.View ArticlePubMedGoogle Scholar
- Muller H, Huttner HB, Kohrmann M, Wielopolski JE, Kornhuber J, Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry. 2010;43:152–3.View ArticlePubMedGoogle Scholar
- Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010;118:309–10.View ArticlePubMedGoogle Scholar
- Cabriales JA, Cooper TV, Taylor T. Prescription drug misuse, illicit drug use, and their potential risk and protective correlates in a Hispanic college student sample. Exp Clin Psychopharmacol. 2013;21:235–44.View ArticlePubMedGoogle Scholar
- Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6:3–16.View ArticlePubMedGoogle Scholar
- Gevirtz C. Anesthesia for opiate detoxification and the ibogaine controversy. Int Anesthesiol Clin. 2011;49:31–48.View ArticlePubMedGoogle Scholar
- Leal MB, de Souza DO, Elisabetsky E. Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochem Res. 2000;25:1083–7.View ArticlePubMedGoogle Scholar
- Ali SF, Newport GD, Slikker Jr W, Rothman RB, Baumann MH. Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. Brain Res. 1996;737:215–20.View ArticlePubMedGoogle Scholar
- Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, et al. Effect of Iboga alkaloids on micro-opioid receptor-coupled G protein activation. PLoS One. 2013;8, e77262.View ArticlePubMedPubMed CentralGoogle Scholar
- Popik P, Layer RT, Fossom LH, Benveniste M, Geter-Douglass B, Witkin JM, et al. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J Pharmacol Exp Ther. 1995;275:753–60.PubMedGoogle Scholar
- Popik P, Wrobel M. Anxiogenic action of ibogaine. Alkaloids Chem Biol. 2001;56:227–33.View ArticlePubMedGoogle Scholar
- Wasterlain CG, Naylor DE, Liu H, Niquet J, Baldwin R. Trafficking of NMDA receptors during status epilepticus: therapeutic implications. Epilepsia. 2013;54 Suppl 6:78–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91–104.PubMedGoogle Scholar
- Cantero JL, Atienza M, Stickgold R, Kahana MJ, Madsen JR, Kocsis B. Sleep-dependent theta oscillations in the human hippocampus and neocortex. J Neurosci. 2003;23:10897–903.PubMedGoogle Scholar
- Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 2012;35:357–74.View ArticlePubMedGoogle Scholar
- Galea S, Lorusso M, Newcombe D, Walters C, Williman J, Wheeler A. Ibogaine – be informed before you promote or prescribe. J Prim Health Care. 2011;3:86–7.PubMedGoogle Scholar
- Alper KR. Ibogaine: a review. Alkaloids Chem Biol. 2001;56:1–38.View ArticlePubMedGoogle Scholar
- Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360:308–9.View ArticlePubMedGoogle Scholar
- Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57:398–412.View ArticlePubMedGoogle Scholar
- Dhir A, Chopra K. Memantine delayed N-Methyl-D-Aspartate (NMDA)-induced convulsions in neonatal rats. Fundam Clin Pharmacol. 2014;29(1):72–8.View ArticlePubMedGoogle Scholar
- Xu H, Ou F, Wang P, Naren M, Tu D, Zheng R. High dosage of agmatine alleviates pentylenetetrazole-induced chronic seizures in rats possibly by exerting an anticonvulsive effect. Exp Ther Med. 2014;8:73–8.PubMedPubMed CentralGoogle Scholar
- Rheims S, Ryvlin P. Pharmacotherapy for tonic-clonic seizures. Expert Opin Pharmacother. 2014;15:1417–26.View ArticlePubMedGoogle Scholar
- Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2015. doi:10.1111/bcp.12720 [Epub ahead of print].Google Scholar
- Binienda ZK, Scallet AC, Schmued LC, Ali SF. Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods. Alkaloids Chem Biol. 2001;56:193–210.View ArticlePubMedGoogle Scholar
- Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115:9–24.View ArticlePubMedGoogle Scholar
- Mazoyer C, Carlier J, Boucher A, Peoc’h M, Lemeur C, Gaillard Y. Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. J Forensic Sci. 2013;58:1666–72.View ArticlePubMedGoogle Scholar